This announcement is a separate document:
精優藥業：完成主要交易領航醫藥及生物科技有限公司所發行可換股債券之條款及條件之建議第三次修訂
EXTRAWELL PHAR: COMPLETION OF MAJOR TRANSACTION CONCERNING THE PROPOSED THIRD AMENDMENTS TO THE TERMS AND CONDITIONS OF THE CONVERTIBLE BONDS ISSUED BY INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.